| Summary: | The liver is an important organ in the body. It is located under the rib cage on the right side. The liver performs many important functions, it processes food for nutrients that the body requires and also helps in the detoxification of harmful materials. Like any organ in the body, the liver is susceptible to diseases such as liver cancer. Liver cancer is the growth and spread of unhealthy cells of the liver. There are several risk factor for liver cancer, these are: Cirrhosis (scarring of the liver), long term hepatitis B and hepatitis C infection and diabetes patients with long term drinking problem. Hepatocellular Carcinoma is the most common form of liver cancer in adult population which begins in the main type of liver cell (hepatocyte). Because Hepatocellular carcinoma starts from the primary liver cell itself (hepatocytes), as such it is a primary liver cancer. About 30,000 Americans are diagnosed with primary liver cancer yearly, making it an important disease that plaques our society and therefore needs proper diagnosis.
In clinical evaluation of primary liver cancer such as HCC, the use of medical imaging technology has been commonplace. Most medical facilities across the country and globally typically use Computed Tomography (CT) and/or Magnetic Resonance Imaging (MRI) in the diagnosis and treatment follow up of Hepatocellular carcinoma. The medical imaging devices are used to determine the extent and volume of the tumor of the cancerous liver cells. In clinical trials involving the imaging of HCC tumors, the typical protocol used in the CT imaging of HCC involves the use of contrast enhanced dual phase acquisition. This approach is based on the physiology of the blood flow through the liver. Since HCC tumors are hypervascular in nature, it would thus be more apparent in the arterial phase of an acquired CT image. The aforementioned characteristic was tested with a volume paradigm which measure and compare the volume of both the arterial phase and portal venous phase acquired images in the experiment. Overall this study helps in furthering goals to reduce the patient dose from the x-ray tubes during clinical trials. The results of the experiments (n = 19, t = 0.67, p = 0.26), indicates no significant difference between the volume of the HCC tumor images acquired both in the AP and PVP.
|
|---|
